JPRN-UMIN000005798招募中1 期
Phase I study of pegylated liposomal doxorubicin and cisplatin combination chemotherapy in patients with recurrent and refractory epithelial ovarian cancer. - Phase I study of pegylated liposomal doxorubicin and cisplatin combination chemotherapy in patients with recurrent and refractory epithelial ovarian cancer.
Cancer Institute Hospital0 个研究点目标入组 18 人开始时间: 2011年6月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)No evidence of interstitial pneumonitis or pulmonary fibrosis on chest X-ray or CT. 2)Patients with a history of severe hypersensitivity reactions to any drugs. 3)Patients with severe heart disease. 4)Patients with active autoimmune disease. 5)Patients with prior diagnosis of malignancy. Exceptios are: - carcinoma in situ - other malignancies curatively treated and >5 years without evidence of recurrence. 6)Patients with an active or uncontrolled infection.(without chronic viral hepatitis.) 7)Patients with other severe deisease(e.g.,renal failure, liver failure, gastrointestinal ulcer) 8)Patienst with massive ascites or/and pleural effusion. 9)Patients with history of hypersensitivity reactions to cisplatin or other platinum. 10) No prior cumulative anthracycline dose in excess of 250mg/m^2. 11)Patients who are decided to be ineligible for this trial by the investigators.
研究者
相似试验
已完成
不适用
Phase I Trail of pegylated liposomal doxorubicin (PLD) in combination with Irinotecan (CPT-11) in Patients with Platinum Refractory and Resistant Ovarian cancerPatients with platinum-refractory and resistant ovarian cancerJPRN-UMIN000005525Fukuoka University, School of Medicine6
进行中（未招募）
不适用
Phase II study of pegylated liposomal doxorubicin (Caelyxâ) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy - AROBASEBreast Cancer Patients with Brain MetastasesMedDRA version: 9.1Level: PTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-006790-81-FRAPREC50
进行中（未招募）
1 期
Phase II study evaluating the combination of liposomal doxorubicin pluscyclophosphamide with trastuzumab followed by docetaxel plustrastuzumab as therapy to be performed before surgery (neoadjuvantchemotherapy) for patients with breast cancer more than 2 cm in size and possible involvement of the lymph nodes adjacent and with the receptor HER2 positive.MedDRA version: 14.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864ocal advanced breast cancer resectable, neoadjuvant settingEUCTR2013-002684-25-ITS.I.C.O.G. ONLUS41
进行中（未招募）
不适用
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal TumorsGynecologic Sarcomas and Mixed Epithelial-Mesenchymal TumorsEUCTR2008-000245-55-DEGYN Research GmbH
招募中
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43